Effect of StentBoost imaging guided percutaneous coronary intervention on mid-term angiographic and clinical outcomes
- Authors
- Oh, Dong Joo; Choi, Cheol Ung; Kim, SunWon; Im, Sung Il; Na, Jin Oh; Lim, Hong Euy; Kim, Jin Won; Kim, Eung Ju; Han, Seong Woo; Rha, Seung-Woon; Park, Chang Gyu; Seo, Hong Seog
- Issue Date
- 30-9월-2013
- Publisher
- ELSEVIER IRELAND LTD
- Keywords
- StentBoost; Percutaneous coronary intervention; Clinical outcomes
- Citation
- INTERNATIONAL JOURNAL OF CARDIOLOGY, v.168, no.2, pp.1479 - 1484
- Indexed
- SCIE
SCOPUS
- Journal Title
- INTERNATIONAL JOURNAL OF CARDIOLOGY
- Volume
- 168
- Number
- 2
- Start Page
- 1479
- End Page
- 1484
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/102122
- DOI
- 10.1016/j.ijcard.2012.12.051
- ISSN
- 0167-5273
- Abstract
- Introduction: The gold standard for evaluating stent expansion after percutaneous coronary intervention (PCI) is intravascular ultrasound (IVUS). However, the routine use of this modality is costly and time consuming. StentBoost is a new imaging technique that improves fluoroscopy-based assessments of stent expansion. The purpose of this study was to evaluate the effect of StentBoost imaging-guided PCI on mid-term angiographic and clinical outcomes. Methods and results: A total of 870 consecutive patients were recruited (mean age: 64.34 +/- 11.61; men: 64.5%), all of whom underwent PCI with drug-eluting stents (DESs). The subjects were divided into a no StentBoost group (n=569 patients) and a StentBoost group (n=301 patients). The 6-month angiographic and 12-month clinical outcomes were compared between the two groups. At 1 month, clinical outcomes were similar between the two groups. At 6 months, the StentBoost group had significantly lower rates of late loss (0.32 +/- 0.40 vs. 0.48 +/- 0.59; p=0.005) and binary restenosis (1.2% vs. 8.3%; p=0.029) compared with the no-StentBoost group. At 12 months, StentBoost group had significantly lower the incidence of target lesion revascularization (TLR) (1.7% vs. 7%; p=0.034) and TLR-major adverse cardiac events (6% vs. 13.2%; p=0.037) compared with the no-StentBoost group. Conclusion: We conclude that the routine clinical use of StentBoost during PCI can be useful, and results in better medium-term angiographic and clinical outcomes. (c) 2013 Elsevier Ireland Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
- Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.